ivacaftor medication used treat cystic fibrosis people certain mutations cystic fibrosis transmembrane conductance regulator cftr gene primarily mutation account cases cystic also included combination medications lumacaftorivacaftor tezacaftorivacaftor elexacaftortezacaftorivacaftor used treat people cystic ivacaftor developed vertex pharmaceuticals conjunction cystic fibrosis foundation first medication treats underlying cause rather symptoms approved us food drug administration fda january one expensive drugs costing per year led criticism high cost combination drug lumacaftorivacaftor approved fda july cystic fibrosis caused one several defects cftr protein regulates fluid flow within cells affects components sweat digestive fluids mucus one defect mutation amino acid glycine g position replaced aspartic acid characterized dysfunctional cftr protein cell surface case protein trafficked correct area epithelial cell surface protein transport chloride channel ivacaftor cftr potentiator improves transport chloride ion channel binding channels directly induce nonconventional mode gating turn increases probability channel ivacaftor used treatment cystic fibrosis people one several specific mutations cystic fibrosis transmembrane conductance regulator cftr protein ivacaftor also included combination product lumacaftorivacaftor single pill used treat people cystic fibrosis mutation ivacaftor also included combination product tezacaftorivacaftor ivacaftor sold symdeko symdeko indicated treat people aged six older two copies mutation symkevi indicated combination regimen ivacaftor mg tablets treatment people cystic fibrosis cf aged twelve years older homozygous mutation heterozygous mutation one following mutations cystic fibrosis transmembrane conductance regulator cftr gene ivacaftor available combination product elexacaftor tezacaftor called trikafta treatment people cystic fibrosis mutation common adverse reactions experienced patients received ivacaftor pooled placebocontrolled phase iii studies abdominal pain versus placebo diarrhoea versus placebo dizziness versus placebo rash versus placebo upper respiratory tract reactions including upper respiratory tract infection nasal congestion pharyngeal erythema oropharyngeal pain rhinitis sinus congestion nasopharyngitis versus placebo headache versus placebo bacteria sputum versus placebo one patient ivacaftor group reported serious adverse reaction abdominal ivacaftor potentiator cftr meaning increases probability defective channel open allow chloride ions pass channel ivacaftor approximately bound plasma proteins primarily alpha glycoprotein albumin ivacaftor bind human red blood ivacaftor extensively metabolised humans vitro vivo data indicate ivacaftor primarily metabolised two major metabolites ivacaftor humans approximately onesixth potency ivacaftor considered pharmacologically active less onefiftieth potency ivacaftor considered pharmacologically following oral administration majority ivacaftor eliminated faeces metabolic conversion major metabolites accounted approximately total dose eliminated negligible urinary excretion ivacaftor unchanged parent apparent terminal halflife approximately hours following single dose fed state apparent clearance clf ivacaftor similar healthy subjects patients cf mean clf mg dose lh healthy subjects steady us food drug administration fda approved ivacaftor january soon afterwards european medicines agency across european lumacaftorivacaftor approved fda july breakthrough therapy status priority cost ivacaftor per year roughly similar price medications extremely rare first nine months second year market ivacaftor sales representing vertexs product sales revenue period total drug development expenses spent cystic fibrosisrelated editorial jama called price ivacaftor exorbitant citing support cystic fibrosis foundation development contribution made fundamental scientific research performed national institutes health relied upon vertex cystic fibrosis drug discovery company responded email publicly funded academic research provided important early understanding cause cystic fibrosis took vertex scientists years research funded mostly company drug cystic fibrosis foundation nonprofit organization dedicated improving healthcare people cystic fibrosis provided million funding development ivacaftor exchange royalty rights event medication successfully developed commercialized foundation sold royalty rights billion foundation stated intends spend funds support vertex said would make medication available free patients united states insurance household income us doctors researchers involved development medication wrote vertex protest price medication set per year uk company provided medication free limited time certain patients left hospitals decide whether continue pay patients uk agencies estimated cost per quality adjusted life year qaly national institute health care excellence medication covered ontario drug benefit plan june government ontario manufacturer negotiated ontario health minister deb matthews called fair price taxpayers negotiations took months estimated around ontarians required medication province alberta began covering medication july september province saskatchewan became third province include provincial medication delay agreement price vertex charge national health plans led patient group protests march combination medication cost year united clinical trials used regulatory approval ivacaftor described approximately cases cystic fibrosis worldwide due mutation called safety efficacy ivacaftor treatment cystic fibrosis patients mutation examined two clinical trialscitation needed first trial performed adults baseline respiratory function normal persons similar age height weight baseline average improvement rapid sustained end weeks people treated ivacaftor average absolute increase vs decline placebo group pulmonary exacerbations reduced half ivacaftor group relative placebo second trial conducted children age six average improvement absolute increase ivacaftor group weeks compared slight decline placebo third clinical trial examined efficacy ivacaftor people cystic fibrosis due mutations trial included people age greater six years used crossover design people trial averaging normal baseline people trial randomized receive either ivacaftor placebo eight weeks followed four eight week washout period group received opposite treatment received first part trial week people treatment ivacaftor experienced average absolute improvement strong dependence efficacy exact mutation patient detailed data different mutation types shown us package httpsenwikipediaorgwikiivacaftor